Quick 30% return possible? Novo Nordisk, D-Wave, and NetraMark shares!

NetraMark Holdings: A quick 30% return?

Is a quick 30% return possible with NetraMark shares? It certainly looks that way. The AI insider tip is being discovered by more and more investors, is now regularly traded on Tradegate, and appears to be finally breaking out of its sideways movement. This clears the way for Zacks Small-Cap Research's price target. Analysts estimate the fair value of the Company, which specializes in clinical trials using its NetraAI technology, at CAD 2.25.

Looking at the news flow of the past few months, a significant price increase would be justified, and it could go much higher. That is because NetraMark helps research-based pharmaceutical and biotech companies save time and money. NetraAI supports the efficient conduct of clinical trials – an area where billions are spent and billions can be saved. Anyone who believes that this can be done just as well with ChatGPT and the like is mistaken. In a comparative test involving three independent studies on schizophrenia, depression, and pancreatic cancer, NetraAI outperformed ChatGPT and the Chinese DeepSeek.

The latest reports from NetraMark show that the Company is consistently putting its technology into practice. Most recently, Asklepion Pharmaceuticals was added as another customer. The Company is using the NetraAI platform in a crucial pediatric Phase 3 study. The study is investigating the efficacy of intravenous L-citrulline (CIT-003-01) in preventing acute lung injury in children who require cardiopulmonary bypass due to congenital heart defects.

The Company is also gearing up for further growth in terms of personnel. Dr. Jan Sedway, an experienced industry expert, has been appointed to the top management team. Sedway brings extensive expertise from senior positions at Clario and Parexel and is expected to strengthen NetraMark, particularly in the areas of oncology and psychiatry—two segments in which demand for innovative study solutions is skyrocketing. Dr. Sedway commented: "NetraMark's technology is reshaping the future of clinical trials by extracting important insights from small, complex data sets and enabling precise study planning. I am very excited to join this dynamic team and contribute to the success of our customers."

D-Wave: New price jump in September?

Is the next price jump for D-Wave shares coming in September? Since May, the share price has been moving sideways in a wide range between EUR 12 and EUR 17.

In a few weeks, the quantum high-flyer will host an important event: On September 17, 2025, the "Qubits Japan" conference will take place in Tokyo for the first time. Under the theme "Quantum Realized," the focus will be on customer projects, technological advances, and scientific milestones. In addition to D-Wave's management, high-ranking representatives from science and industry will also speak at the conference. D-Wave CEO Alan Baratz recently highlighted Japan's special role. The country is the cradle of the quantum annealing concept, which was developed nearly 30 years ago. Today, a dynamic ecosystem is emerging in Asia that is contributing significantly to the practical implementation of quantum applications. The Qubits conference aims to further intensify this exchange. D-Wave Quantum is significantly expanding its presence in the Asia-Pacific region (APAC). The Company has seen an 83% increase in bookings for its quantum annealing technology over the past twelve months. This is due to growing demand for applications in the areas of optimization and artificial intelligence (AI).

Successful projects by Asian customers will also be presented at the event on September 17. For example, the pharmaceutical division of Japan Tobacco uses D-Wave's quantum AI in drug discovery. Following a successful proof of concept in the spring, a pilot project is now underway to develop novel molecular structures. NTT DOCOMO, Japan's largest mobile phone provider, is also involved. D-Wave's technology is expected to enhance network performance in this area. Optimization of paging signals reduced network congestion by 15% – with the potential for lower infrastructure costs. The method is now in use nationwide. In South Korea, a strategic cooperation agreement has been signed with Yonsei University and the city of Incheon to promote research, talent development, and concrete applications in areas such as biotechnology and materials science. There are also plans to purchase a D-Wave Advantage2™ system for the campus in Incheon.

Novo: Share price remains volatile

Novo Nordisk's share price simply cannot settle down. For a company with a market capitalization of over EUR 200 billion, the price swings are massive. The share price rose by around 10% between Wednesday and Monday. There was some positive news over the weekend. Wegovy celebrated a strong market launch in South Korea. Doctors and patients in South Korea appear to prefer Wegovy, which has already established itself as a blockbuster in the US and Europe. According to media reports, the weight loss drug has already been sold over 400,000 times within eight months. This means that the drug has a share of around 82% of the total obesity market there. Novo Nordisk is thus underlining its ability to quickly gain a foothold in new markets and continue its international growth.

But the joy among shareholders was short-lived. On Monday, competitor Eli Lilly announced its latest success in clinical development. In a Phase 3 study, the oral weight loss pill Orforglipron demonstrated an average weight reduction of more than 10% in patients with diabetes. The result reinforces the appeal of oral alternatives—especially since tablets are easier for many patients to use than injections such as Wegovy. Investors reacted promptly: Novo Nordisk shares slipped from EUR 49.61 to almost EUR 47 since Monday afternoon. According to Deutsche Bank, these are currently clear buy prices. Analysts recently confirmed their "Buy" recommendation. They believe the share price could reach around EUR 80.

NetraMark is an exciting AI player with a focus on the pharmaceutical and biotech industries. The potential is enormous, and the share price appears to be breaking out to the upside. In contrast, Novo Nordisk remains very volatile, requiring not just strong nerves but also patience from investors. In contrast, things are likely to get exciting again at D-Wave as early as September, with news flow anticipated around the event in Tokyo.